The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside

T Liu, S Li, S Ying, S Tang, Y Ding, Y Li, J Qiao… - Frontiers in …, 2020 - frontiersin.org
Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by
the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is …

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

CA Elmets, CL Leonardi, DMR Davis… - Journal of the American …, 2019 - Elsevier
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with
awareness and attention to comorbidities - ScienceDirect Skip to main contentSkip to article …

Psoriasis: comorbidities

F Yamazaki - The Journal of dermatology, 2021 - Wiley Online Library
Psoriasis has long been known as a disease with many complications, but was attributed to
diet and obesity. However, in recent years, psoriasis itself has been recognized as a series …

A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial)

JM Gelfand, DB Shin, A Alavi, DA Torigian… - Journal of Investigative …, 2020 - Elsevier
Psoriasis is a T helper type 17 autoimmune disease associated with an increased risk
cardiovascular events and mortality. Ustekinumab, an antibody to p40, blocks cytokines IL …

The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study …

S Mehrmal, P Uppal, N Nedley, RL Giesey… - Journal of the American …, 2021 - Elsevier
Background Few existing studies on the global incidence, prevalence, and burden of
disease from psoriasis are of high quality, making reliable data and comparisons difficult to …

Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies

MT Patrick, H Zhang, R Wasikowski, EP Prens… - Journal of Allergy and …, 2021 - Elsevier
Background Coronavirus disease 2019 (COVID-19) is commonly associated with skin
manifestations, and may also exacerbate existing skin diseases, yet the relationship …

A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S)

JM Gelfand, DB Shin, KC Duffin, AW Armstrong… - Journal of Investigative …, 2020 - Elsevier
Psoriasis, a chronic immune-mediated disease, is associated with an increased risk of
cardiovascular events and mortality. Secukinumab selectively neutralizes IL-17A and has …

Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis

G Tsuji, A Hashimoto-Hachiya, VH Yen… - Cell death …, 2020 - nature.com
Psoriasis is a systemic inflammatory disease significantly associated with comorbidities
including type 2 diabetes mellitus (T2DM). Metformin is utilized as a first-line agent for …

National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 1

JM Gelfand, AW Armstrong, S Bell, GL Anesi… - Journal of the American …, 2020 - Elsevier
Objective To provide guidance about management of psoriatic disease during the
coronavirus disease 2019 (COVID-19) pandemic. Study design A task force (TF) of 18 …

Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways

S Piaserico, G Orlando, F Messina - International Journal of Molecular …, 2022 - mdpi.com
A convincing deal of evidence supports the fact that severe psoriasis is associated with
cardiovascular diseases. However, the precise underlying mechanisms linking psoriasis …